Shattuck Labs, Inc. Debt Securities Available For Sale Excluding Accrued Interest Current
Shattuck Labs, Inc. (STTK) had Debt Securities Available For Sale Excluding Accrued Interest Current of $145.00 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent · last filed 2026-08-11
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest Current $145.00M.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest Current $0.00.
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest Current $23.87M.
- 2025-09-30: Debt Securities Available For Sale Excluding Accrued Interest Current $43.58M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest Current |
|---|---|
| 2026-06-30 | $145.00M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | $23.87M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $43.58M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 |
| 2024-12-31 | $15.60M 10-K · filed 2026-03-05 |
| 2024-09-30 | $46.23M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $44.65M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $38.63M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $5.00M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |